JMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating tri-specific antibody for safe and potent immunotherapy

mAbs 2026 Open access

Read full text
Authors: Chunyin Gu, Deyi Wang, Yan Wang, Fangfang Jia, Fu Zhou, Shun Chang, Kedong Ouyang, Yu Zhao, Linlin Liu, Huawei Zhang, Peipei Liu, Haixiang Yu
+3 more Xiaodan Cao, Taylor B. Guo, Huanzhang Xia
DOI: 10.1080/19420862.2026.2709956
Cited by: 1
References: 34

Abstract

T cells and display enhanced anti-tumor efficacy with good tolerability. To our knowledge, this is the first tri-specific antibody of its kind that targets specifically IL2/15 receptor signaling subunits.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Psoriasis: Treatment and Pathogenesis Inflammasome and immune disorders

Publication details

Journal / source
mAbs
Publisher
Informa UK Limited
Volume
18
Issue
1
Pages
2709956–2709956
Publication date
2 August 2026
Language
EN